21 results
Thumbnail

D3.66 - National Survey on Perioperative Hypersensitivity Reactions: Clinical and Epidemiological Insights from Spanish Hospitals

Thumbnail

D3.67 - Desensitization to Pertuzumab in a Patient with a Mixed Hipersensitivity Reaction

Thumbnail

D3.69 - Tissue-Specific Allergen Distribution in Blue Swimmer Crab (Portunus pelagicus): Implications for Shellfish Allergy Diagnostics

Thumbnail

D3.70 - Multiple Food Protein-Induced Enteropathy Syndrome: The Role of Skin Patch Testing in Guiding Effective Decision-Making

Thumbnail

D3.71 - Anaphylaxis Induced by Macrogol: A Case Report

Thumbnail

D3.72 - Utility of Basophil Activation Testing in Drug and Peanut Allergy: Concordance with Clinical Outcomes

Thumbnail

D3.73 - Review of skin testing for delay hypersensitivity drug reactions, possible covariates involved in the results

Thumbnail

D3.77 - Hypersensitivity Reactions to Iodinated Contrast Media: A Single-Center Experience

Thumbnail

D3.78 - A rare case of scombroid syndrome with hypotension and biphasic course

Thumbnail

D3.79 - Occupational Asthma due to Inhaled Mare's Milk Exposure and Anaphylaxis Associated with Plantago ovata

Thumbnail

D3.82 - Could Lipid Transfer Protein Induced Anaphylaxis Be a Surprising Outcome of Sleeve Gastrectomy?

Thumbnail

D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab

Thumbnail

D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab

Thumbnail

D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis

Thumbnail

D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic

Thumbnail

D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates

Thumbnail

D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab

Thumbnail

D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results

Thumbnail

D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years

Thumbnail

D1.369 - Characteristics of patients with severe asthma undergoing biological treatment at a reference center